Literature DB >> 22958322

Rituximab treatment in a case of antisynthetase syndrome with severe interstitial lung disease and acute respiratory failure.

Maria Cristina Zappa1, Tiziana Trequattrini, Francesco Mattioli, Rosario Rivitti, Rossana Vigliarolo, Antonella Marcoccia, Giovanni D'Arcangelo.   

Abstract

We present a case of severe interstitial pneumonitis, mild polyarthritis and polymyositis, and Raynaud's syndrome with the presence of anti-Jo-1 antibodies, which had been diagnosed as anti-synthetase syndrome. The presence, however, of anti-Ro/SSA antibodies led us to understand that we were dealing here with a more severe form of interstitial lung disease. The patient was treated for acute respiratory failure but he showed resistance to glucocorticoids and cyclosporine. Thus, he was treated with infusions of anti-CD20 therapy (rituximab): his clinical conditions improved very rapidly and a significant decrease in the activity of pulmonary disease was detected using high-resolution computerized tomography (HRCT) of the thorax and pulmonary function tests.

Entities:  

Year:  2011        PMID: 22958322      PMCID: PMC3463069          DOI: 10.1186/2049-6958-6-3-183

Source DB:  PubMed          Journal:  Multidiscip Respir Med        ISSN: 1828-695X


  8 in total

1.  Rituximab in the treatment of antisynthetase syndrome.

Authors:  L Brulhart; J-M Waldburger; C Gabay
Journal:  Ann Rheum Dis       Date:  2006-07       Impact factor: 19.103

2.  [Acute respiratory distress syndrome as the presenting manifestation of an antisynthetase syndrome].

Authors:  D Fagedet; S Bernard; B Colombe; A Bosseray; A Baudet; L Bouillet; C Massot
Journal:  Rev Med Interne       Date:  2008-10-30       Impact factor: 0.728

3.  Rituximab in the treatment of dermatomyositis: an open-label pilot study.

Authors:  Todd D Levine
Journal:  Arthritis Rheum       Date:  2005-02

4.  Rituximab in life threatening antisynthetase syndrome.

Authors:  E Vandenbroucke; J C Grutters; J Altenburg; W G Boersma; E J ter Borg; J M M van den Bosch
Journal:  Rheumatol Int       Date:  2009-02-01       Impact factor: 2.631

5.  Rituximab treatment of the anti-synthetase syndrome: a retrospective case series.

Authors:  Marthe Sem; Oyvind Molberg; May Brit Lund; Jan Tore Gran
Journal:  Rheumatology (Oxford)       Date:  2009-06-16       Impact factor: 7.580

6.  Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis.

Authors:  Jonathan C W Edwards; Leszek Szczepanski; Jacek Szechinski; Anna Filipowicz-Sosnowska; Paul Emery; David R Close; Randall M Stevens; Tim Shaw
Journal:  N Engl J Med       Date:  2004-06-17       Impact factor: 91.245

7.  Rituximab for refractory polymyositis: an open-label prospective study.

Authors:  Chi Chiu Mok; Ling Yin Ho; Chi Hung To
Journal:  J Rheumatol       Date:  2007-09       Impact factor: 4.666

Review 8.  Antisynthetase syndrome.

Authors:  Agathe Imbert-Masseau; Mohamed Hamidou; Christian Agard; Jean Yves Grolleau; Pascal Chérin
Journal:  Joint Bone Spine       Date:  2003-06       Impact factor: 4.929

  8 in total
  6 in total

1.  [Rituximab for the treatment of poly- and dermatomyositis : Results from the GRAID-2 registry].

Authors:  C Fiehn; L Unger; H Schulze-Koops; F Proft; J C Henes; A Jacobi; T Dörner
Journal:  Z Rheumatol       Date:  2018-02       Impact factor: 1.372

Review 2.  Biologic therapy in the idiopathic inflammatory myopathies.

Authors:  Thomas Khoo; Vidya Limaye
Journal:  Rheumatol Int       Date:  2019-11-04       Impact factor: 2.631

3.  Immune-mediated necrotising myopathy associated with antibodies to the signal recognition particle treated with a combination of rituximab and cyclophosphamide.

Authors:  Marisa Fernandes das Neves; Joana Caetano; Susana Oliveira; José Delgado Alves
Journal:  BMJ Case Rep       Date:  2015-08-03

4.  Association between nonspecific interstitial pneumonia and presence of CD20+ B lymphocytes within pulmonary lymphoid follicles.

Authors:  Min Peng; Wenze Wang; Ling Qin; Hongrui Liu; Mingwei Qin; Wenjie Zheng; JuHong Shi; Wenbing Xu; Yuanjue Zhu
Journal:  Sci Rep       Date:  2017-12-05       Impact factor: 4.379

5.  Effect of Genetic and Laboratory Findings on Clinical Course of Antisynthetase Syndrome in a Hungarian Cohort.

Authors:  Katalin Szabó; Levente Bodoki; Melinda Nagy-Vincze; Anett Vincze; Erika Zilahi; Peter Szodoray; Katalin Dankó; Zoltán Griger
Journal:  Biomed Res Int       Date:  2018-10-25       Impact factor: 3.411

6.  Early Recognition and Successful Treatment of Anti-synthetase Syndrome.

Authors:  Arabi Rasendrakumar; Aakanksha Khanna; Smita Bakhai
Journal:  Cureus       Date:  2022-01-31
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.